Genitope Corporation - Earning & Dividend Analysis Snapshot

This detailed Report provides an Earnings and Dividends history for Genitope Corporation. Tabular results include up to a ten-year history of "as reported" Earnings per Share and Dividends per Share plus a calculation of the amount of earnings paid out over the year in dividends (i.e. Payout Ratio). Earnings and Dividends are presented on both a Quarterly and Annual basis. An annual Percent Change factor is calculated for both Earnings and Dividends.

Genitope Corporation. The Group's principal activities are to research and develop immunotherapies for the treatment of cancer. Immunotherapies are treatments that utilize the immune system to combat diseases. The Group's product, MyVax personalized immunotherapy, is a patient-specific active immunotherapy that is based on the genetic makeup of a patient's tumor and is designed to activate a patient's immune system to identify and attack cancer cells. The MyVax is currently in a pivotal Phase 3 clinical trial and additional Phase 2 clinical trials for the treatment of B-cell non-Hodgkin's lymphoma. The Group's Phase III clinical trial is for the treatment of follicular B-cell NHL. The Group is also developing MyVax for the treatment of chronic lymphocytic leukemia (CLL). The Group operates in the domestic market.

Not the Report you are looking for? Click here for more browsing options.

view sample Single Report

view sample All Basic Reports

Layout and Content of a Typical Report